When people think of the potential for artificial intelligence to impact the biopharmaceutical industry, the focus is usually on drug discovery or in the clinic to help guide decision making with regards to pairing the right drug to the right patient. Yseop is focused on a more mundane use for the technology—the writing of clinical data reports. The company had been working in the financial services industry when it was approached by Sanofi to see if it could apply its natural language generation to make the creation of these reports faster and less expensive. We spoke to Emmanuel Walckenaer, CEO of Yseop, about artificial intelligence, its potential to change the way biopharmaceutical companies work in non-obvious ways, and why a large number of biopharmaceutical companies are turning AI to do more with less.

How AI Is Finding Its Way into Unexpected Places in Biopharma Companies

Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries.  With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization.   Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.

Welcome to AI Uncovered!

The first episode features a conversation with Craig Vachon, CEO of AI Redefined (AIR) and Head of US Operations at NextStage AM. Craig is an angel investor, author, TED speaker, and chairman of Yseop. 

Tim and Craig discuss the AI landscape as it exists today and then go into the benefits and limitations of ChatGPT and LLMs, especially for more regulated industries. They touch on some of the challenges involved with AI startups, advice for entrepreneurs, and practical considerations of rolling out AI technology to customers.

AI Uncovered

Craig Vachon - “I still think ChatGPT is kind of a gimmick”

The second episode features a conversation with Emmanuel Walckenaer, CEO of Yseop. Yseop is reimagining the future of scientific writing through generative AI. The company's mission is to get medicine into the hands of those who need it, faster.

Tim and Emmanuel shares insights on the state of natural language generation (NLG) today and the roots of the technology. They discuss how generative AI is automating parts of the clinical document landscape and why the tech is helping scientific writers be more productive.

E. Walckenaer - In the next 5 years, 80% of the life sciences industry will be using this type of AI

We welcome Marjo Gazak to AI Uncovered. Marjo is a life sciences expert with over 22 years of experience in drug development, regulatory submissions, document development innovation and data mining systems. Tim and Marjo discuss a wide range of topics, from the emergence of automation in the drug delivery process to the future role of generative AI in helping this regulated industry get drugs to market faster.  

Marjo has worked at Eli Lilly and more recently at FibroGen, where she is the Senior Director in Regulatory Affairs and Medical Writing. She has BS and MS degrees in Zoology from Clemson University and a PHD in Aquatic Toxicology from Louisville.

Marjo Gazak - What used to take 8 hours, I can now generate a first draft in 1 second

We welcome Gregor Mittersinker to AI Uncovered. Gregor is the founder and creative director at Loft. Loft focuses on product development and design with a specialty in building large product ecosystems. 

In this episode, Tim and Gregor dive deep into UX and design. They discuss how LLMs, like ChatGPT, have impacted UI design, specifically around conversational UI and prompt interfaces. They evaluate how industry specific applications might use a variety of UI techniques to deal with the nuances of AI in the future.

Gregor brings over 30 years of experience to product development and design. He holds over 100 patents and has worked with brands such as Bose, 3M, Dell, Square and Segate. Gregor has a BA and MA from the Technical University Vienna and University of Applied arts in Vienna. Gregor is currently an adjunct professor at the RISD (Rhode Island School of Design).

Gregor Mittersinker - AI, ChatGPT, and the Impact on UX & Design

We welcome Daniel O'Mahony to AI Uncovered. Daniel is a senior manager of sales and business consulting with Körber Pharma, a pharma manufacturing software company. Along with his work at Körber, Dan lectures with the national institute of bioprocessing research and training and at the Atlantic Technical University covering topics like BioPharma 4.0 and digital transformation.

In this episode, Tim and Dan look at the impact of AI on the pharmaceutical manufacturing processes and the delicate balance between digital transformation, risk, and productivity gains in life sciences. They discuss why Ireland has been a hub for manufacturing and pharmaceutical growth over the last 60 years. Next, they dig into the digital transformation happening in drug manufacturing, the role of AI on the process, and the future of personalized drugs. 

Dan has a masters degrees in bioprocessing from Atlantic Technical University and in Pharmaceutical business and technology from Griffith College. He is based in Dublin, Ireland.

Daniel O'Mahony - BioPharma 4.0 & The Role of AI in Drug Manufacturing

We welcome Fred Schonenberg to AI Uncovered. Fred is the founder and CEO of VentureFuel. He has created an innovation framework that bridges the VC, Angel, and Startup ecosystem with enterprises to deliver tangible technology solutions that drive growth. In his role at Venture Fuel, Fred has worked with over 100 companies from General Mills to Netflix.

He is a frequent speaker at industry events such as SXSW, Ad Tech, and Advertising Week and is published in broad media publications including Huffington post, Creator Magazine and Ad Week.

In this episode Tim and Fred discuss generative AI and the role and collaboration between venture capital firms, startups, and enterprises. Fred has worked with over 100 companies, from General Mills to Beam Suntory to Netflix. He has helped companies discover and implement new technologies and delivered breakthrough results including an 18.7% uptick in sales , $10m+ savings, and 5x increase in purchase intent.

Fred Schonenberg - The Vital Role of GenAI in Enterprises

We’re excited to welcome Oeystein Kjoersvik to AI Uncovered. Oeystein leads the Generative AI program within the Quality Assurance team at Merck, where he focuses on developing AI tools and applying a quality-first approach to ensure safe, effective use of AI in GxP-regulated environments.

In this episode, Tim and Oeystein delve into the challenges of adopting AI in regulated settings, the complexity of validating GenAI tools, and the transition from traditional processes to AI-augmented systems. They also explore Oeystein’s work with the IMPALA Consortium and the importance of cross-industry collaboration to identify and scale high-value use cases for Generative AI.

Before his current role, Oeystein served as a Product Owner in Analytics at Merck IT, building analytics platforms and integrating data science across systems. He also contributed as a Machine Learning Subject Matter Expert to TransCelerate’s Intelligent Automation Group, advancing AI applications in pharmacovigilance.

Oeystein brings a rare blend of technical expertise and regulatory insight. He’s passionate about helping teams adopt AI responsibly and transparently—ensuring innovation aligns with quality across the pharmaceutical landscape.

Oeystein Kjoersvik - Auditing AI: Quality, Compliance & the Role of GenAI in Pharma

Welcome to AI Uncovered, a podcast for technology enthusiasts that explores the intersection of generative AI, machine learning, and innovation across regulated industries. With the AI software market projected to reach $14 trillion by 2030, each episode features compelling conversations with an innovator exploring the impact of generative AI, LLMs, and other rapidly evolving technologies across their organization. Hosted by Executive VP of Product at Yseop, Tim Martin leads a global team and uses his expertise to manage the wonderful world of product.

Oeystein Kjoersvik - Auditing AI: Quality, Compliance & the Role of GenAI in Pharma

Yseop

Related tracks